Ligand Pharmaceuticals Inc
LGND191.240USD
-0.070-0.04%
Fechamento 11/03, 16:00（ET）Cotações atrasadas em 15 min
3.71BValor de mercado
PerdaP/L TTM
Mais detalhes de Ligand Pharmaceuticals Inc Empresa
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
Informações de Ligand Pharmaceuticals Inc
Código da empresaLGND
Nome da EmpresaLigand Pharmaceuticals Inc
Data de listagemNov 18, 1992
CEOMr. Todd C. Davis
Número de funcionários68
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 18
Endereço555 Heritage Drive, Suite 200
CidadeJUPITER
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal33458
Telefone18585507500
Sitehttps://www.ligand.com/
Código da empresaLGND
Data de listagemNov 18, 1992
CEOMr. Todd C. Davis
Executivos da empresa Ligand Pharmaceuticals Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
127.16K
-7.29%
Dr. John W. Kozarich ,Ph.D.
Dr. John W. Kozarich ,Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
43.90K
-1.05%
Dr. Stephen L. Sabba, M.D.
Dr. Stephen L. Sabba, M.D.
Independent Director
Independent Director
35.05K
+3.57%
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Independent Director
Independent Director
31.98K
+3.93%
Mr. Andrew Reardon
Mr. Andrew Reardon
Chief Legal Officer
Chief Legal Officer
15.72K
-7.77%
Mr. Octavio (Tavo) Espinoza
Mr. Octavio (Tavo) Espinoza
Chief Financial Officer
Chief Financial Officer
10.12K
+2.26%
Dr. Nancy Ryan Gray, Ph.D.
Dr. Nancy Ryan Gray, Ph.D.
Independent Director
Independent Director
9.35K
+14.86%
Mr. Jason Haas
Mr. Jason Haas
Independent Director
Independent Director
6.86K
+21.40%
Dr. Martine Zimmermann, Pharm.D.
Dr. Martine Zimmermann, Pharm.D.
Independent Director
Independent Director
4.17K
-2.68%
Mr. Todd C. Davis
Mr. Todd C. Davis
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
127.16K
-7.29%
Dr. John W. Kozarich ,Ph.D.
Dr. John W. Kozarich ,Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
43.90K
-1.05%
Dr. Stephen L. Sabba, M.D.
Dr. Stephen L. Sabba, M.D.
Independent Director
Independent Director
35.05K
+3.57%
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Independent Director
Independent Director
31.98K
+3.93%
Mr. Andrew Reardon
Mr. Andrew Reardon
Chief Legal Officer
Chief Legal Officer
15.72K
-7.77%
Mr. Octavio (Tavo) Espinoza
Mr. Octavio (Tavo) Espinoza
Chief Financial Officer
Chief Financial Officer
10.12K
+2.26%
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Kyprolis
8.80M
18.48%
Captisol
8.29M
17.40%
Filspari
6.58M
13.81%
Qarziba
5.88M
12.36%
Royalties Other
5.43M
11.41%
Outro
12.64M
26.54%
Sem dados
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Kyprolis
8.80M
18.48%
Captisol
8.29M
17.40%
Filspari
6.58M
13.81%
Qarziba
5.88M
12.36%
Royalties Other
5.43M
11.41%
Outro
12.64M
26.54%
Distribuição de ações
Atualizado em: dom, 2 de nov
Atualizado em: dom, 2 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
13.55%
The Vanguard Group, Inc.
10.64%
Janus Henderson Investors
5.41%
Macquarie Investment Management
4.73%
State Street Investment Management (US)
3.83%
Outro
61.85%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
13.55%
The Vanguard Group, Inc.
10.64%
Janus Henderson Investors
5.41%
Macquarie Investment Management
4.73%
State Street Investment Management (US)
3.83%
Outro
61.85%
Tipos de investidores
Investidores
Proporção
Investment Advisor
58.05%
Investment Advisor/Hedge Fund
38.85%
Individual Investor
2.29%
Pension Fund
1.60%
Research Firm
1.26%
Bank and Trust
0.45%
Hedge Fund
0.45%
Sovereign Wealth Fund
0.10%
Venture Capital
0.04%
Participação acionária institucional
Atualizado em: dom, 5 de out
Atualizado em: dom, 5 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
538
19.85M
101.27%
-443.72K
2025Q2
535
19.71M
102.13%
-738.05K
2025Q1
554
19.82M
102.82%
-711.89K
2024Q4
546
19.28M
100.16%
-1.51M
2024Q3
543
19.17M
104.83%
-583.22K
2024Q2
527
18.31M
101.74%
-865.78K
2024Q1
520
17.60M
99.35%
-393.03K
2023Q4
527
16.97M
97.29%
-861.76K
2023Q3
515
17.24M
99.38%
-910.17K
2023Q2
526
17.09M
98.94%
-1.02M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
2.65M
13.55%
-19.35K
-0.72%
Jun 30, 2025
The Vanguard Group, Inc.
2.08M
10.64%
+33.19K
+1.62%
Jun 30, 2025
Janus Henderson Investors
1.06M
5.41%
+33.19K
+3.23%
Jun 30, 2025
Macquarie Investment Management
926.55K
4.73%
+20.33K
+2.24%
Jun 30, 2025
State Street Investment Management (US)
749.75K
3.83%
+22.63K
+3.11%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
704.52K
3.6%
-40.41K
-5.42%
Jun 30, 2025
Congress Asset Management Company, LLP
647.94K
3.31%
+5.23K
+0.81%
Jun 30, 2025
Chicago Capital, LLC
571.83K
2.92%
+17.31K
+3.12%
Jun 30, 2025
Stephens Investment Management Group, LLC
604.81K
3.09%
-2.41K
-0.40%
Jun 30, 2025
MFS Investment Management
339.74K
1.73%
+61.95K
+22.30%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 2 de nov
Atualizado em: dom, 2 de nov
Nome
Proporção
Franklin Genomic Advancements ETF
3.58%
Invesco Pharmaceuticals ETF
3%
Virtus LifeSci Biotech Products ETF
2.58%
SPDR S&P Pharmaceuticals ETF
2.56%
Invesco S&P SmallCap Health Care ETF
2.21%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.92%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.73%
Invesco Dorsey Wright Healthcare Momentum ETF
1.65%
iShares U.S. Pharmaceuticals ETF
1.28%
OneAscent Small Cap Core ETF
0.97%
Ver Mais
Franklin Genomic Advancements ETF
Proporção3.58%
Invesco Pharmaceuticals ETF
Proporção3%
Virtus LifeSci Biotech Products ETF
Proporção2.58%
SPDR S&P Pharmaceuticals ETF
Proporção2.56%
Invesco S&P SmallCap Health Care ETF
Proporção2.21%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção1.92%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proporção1.73%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporção1.65%
iShares U.S. Pharmaceuticals ETF
Proporção1.28%
OneAscent Small Cap Core ETF
Proporção0.97%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
